Marzena Szwed
Overview
Explore the profile of Marzena Szwed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szwed M, Jost T, Majka E, Gharibkandi N, Majkowska-Pilip A, Frey B, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004038
Near-infrared light (NIR)-responsive metal-based nanoparticles (NPs) could be used for tumour therapy. We examined how platinum (Pt), gold (Au), and core-shell Pt-Au NPs affect the viability of human hepatocellular carcinoma...
2.
Szwed M, Poczta-Krawczyk A, Kania K, Wiktorowski K, Podsiadlo K, Marczak A, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39940670
The clinical application of paclitaxel (PTX), a widely used anticancer drug, is constrained by cardiac arrhythmias and disruptions in vascular homeostasis. To mitigate the non-specific, high toxicity of PTX towards...
3.
Bednarska-Szczepaniak K, Halagan K, Szwed M, Przelazly E, Lesnikowski Z
J Chem Inf Model
. 2024 Aug;
64(16):6521-6541.
PMID: 39140958
A relationship between the electronic properties of metal ions in metallacarboranes and their ability to modulate mitochondrial oxidase activity and membrane hyperpolarization in cancer cells was demonstrated. Quantum chemistry methods,...
4.
Szwed M, Marczak A
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539491
Hyperthermia (HT) is an anti-cancer therapy commonly used with radio and chemotherapies based on applying heat (39-45 °C) to inhibit tumor growth. However, controlling heat towards tumors and not normal...
5.
Szwed M, Michlewska S, Kania K, Szczech M, Marczak A, Szczepanowicz K
Cells
. 2023 Aug;
12(16).
PMID: 37626862
The low distribution of hydrophobic anticancer drugs in patients is one of the biggest limitations during conventional chemotherapy. SDS-based polyelectrolyte multicore nanocarriers (NCs) prepared according to the layer by layer...
6.
Wawrowicz K, Majkowska-Pilip A, Szwed M, Zelechowska-Matysiak K, Chajduk E, Bilewicz A
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499101
Overcoming the limitations for efficient and selective drug delivery is one of the most challenging obstacles for newly designed anticancer agents. In this study, we present two types of platinum-based...
7.
Bednarska-Szczepaniak K, Przelazly E, Kania K, Szwed M, Litecka M, Gruner B, et al.
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359756
Platinum compounds remain the first-line drugs for the treatment of most lethal gynecological malignancies and ovarian cancers. Acquired platinum resistance remains a major challenge in gynecological oncology. Considering the unique...
8.
Glowacki S, Synowiec E, Szwed M, Toma M, Skorski T, Sliwinski T
Biomolecules
. 2021 Apr;
11(4).
PMID: 33924068
Chronic myeloid leukemia (CML) develops due to the presence of the BCR-ABL1 protein, a target of tyrosine kinase inhibitors (TKIs), such as imatinib (IM), used in a CML therapy. CML...
9.
Wigner P, Zielinski K, Labieniec-Watala M, Marczak A, Szwed M
Sci Rep
. 2021 Feb;
11(1):4544.
PMID: 33633284
Doxorubicin (DOX) is considered one of the most powerful chemotherapeutic agents but its clinical use has several limitations, including cardiomyopathy and cellular resistance to the drug. By using transferrin (Tf)...
10.
Wigner P, Zielinski K, Michlewska S, Danielska P, Marczak A, Ricci E, et al.
Sci Rep
. 2021 Feb;
11(1):3849.
PMID: 33589697
Even though application of nanoparticles in medicine seems to provide unique solutions for drug delivery and diagnosis diseases, understanding interactions between nanoscale materials and biological systems is imperative. Therefore, this...